Jci_page_head_homepage_01 Jci_page_head_homepage_02
Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass
Published in Volume 119, Issue 2
J Clin Invest. 2009; 119(2):408–420 doi:10.1172/JCI35620
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
Amelioration of pressure load–induced cardiac hypertrophy/remodeling via PDE5 inhibition with sildenafil is absent in Rgs2–/– mice.

(A) Sildenafil (Sil) suppressed hypertrophy in Rgs2+/+, but not Rgs2–/–, mice (n = 8–13 per group). (B and C) Representative echocardiograms and summary data showing response to 1 wk TAC (T) with or without sildenafil treatment (n = 7–9 per group). S, sham. (D) Effects of sildenafil on LV PV loops. (E) Sildenafil did not alter the increase in LV afterload in either genotype (n = 4–7 per group). (F) Summary invasive PV loop results (n = 4–7 per group). Sildenafil improved systolic and diastolic function in Rgs2+/+ TAC hearts, but had no effect in Rgs2–/– TAC hearts. *P < 0.05 versus respective sham control; P < 0.05 versus respective 1 wk TAC; P < 0.05 versus Rgs2+/+ TAC; §P < 0.05 versus Rgs2–/– sham.